Recep DEMİRBAĞ, Abdullah TAŞKIN, Kaan KIRALİ, Murat Bülent RABUŞ, Nurten AKSOY, Yusuf SEZEN, Mehmet TAŞAR, Cevat YAKUT

Serum prolidase activity in patients with degenerative and rheumatic heart valve diseases

It is known that renin-angiotensin system, inflammation, signaling pathways, and genetic predisposition play a major role in the pathogenesis of heart valve disease. Scarring and collagen deposition in the valves and destruction of myocytes may result from the combined effects of rheumatic and degenerative process in heart valve diseases. Prolidase plays an important role in collagen metabolism, matrix remodeling and cell growth. The aim of the study was to comparatively assess the serum prolidase activity in rheumatic and degenerative heart valve diseases. Materials and methods: The study included 26 patients who had undergone valve replacement due to rheumatic etiology (Group I), 24 patients who had undergone valve replacement due to degenerative etiology (Group II) and 20 healthy volunteers (Group III). Prolidase activity was determined in all subjects. High sensitive C-reactive protein and white blood cell count were studied in only valve patients. Results: Prolidase activity was significantly greater in control group than in patients group (51.23.± 5.9 U/L vs. 39.40 ± 4.6 U/L, respectively; P < 0.001). There was no statistically significant difference between Group I and Group II (P = 0.721). No correlation was detected between serum prolidase activity and severity of valve disease (P > 0.05). Conclusion: These results suggested that rheumatic and degenerative heart valve diseases seem to be associated with decreased serum prolidase activity.

Anahtar Kelimeler:

Key words: Prolidase activity, rheumatic valve disease, degenerative valve disease

Serum prolidase activity in patients with degenerative and rheumatic heart valve diseases

Keywords:

Key words: Prolidase activity, rheumatic valve disease, degenerative valve disease,

PDF

___

1. O’Brien KD. Pathogenesis of calcific aortic valve disease: A disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol 2006; 26: 1721-8.
2. Stollermann GH. Rheumatic fever. Lancet 1997; 349: 935-42.
3. Davutoglu V, Celik A, Aksoy M. Contribution of selected serum inflammatory mediators to the progression of chronic rheumatic valve disease, subsequent valve calcification and NYHA functional class. J Heart Valve Dis 2005; 14: 251-6.
4. Bahler RC, Desser DR, Finkelhor RS, Brener SJ, Youssefi M. Factors leading to progression of valvular aortic stenosis. Am J Cardiol 1999; 84: 1044-8.
5. Walton KW, Williamson N, Johnson AG. The pathogenesis of atherosclerosis of the mitral and aortic valves. J Pathol 1970; 101: 205-20.
6. Schoen FJ, St John Sutton M. Contemporary pathologic considerations in valvular disease. In: Virmani B, Atkinson JB, Feuoglio JJ, editors. Cardiovascular pathology. Philadelphia: Saunders; 1991. p.334-53.
7. Bishop JE. Regulation of cardiovascular collagen deposition by mechanical forces. Mol Med Today 1998; 4: 69-75.
8. Edep ME, Shirani J, Wolf P, Brown DL. Matrix metalloproteinase expression in nonrheumatic aortic stenosis. Cardiovasc Pathol 2000; 9: 281-6.
9. Soini Y, Satta J, Maatta M, Autio-Harmainen H. Expression of MMP2, MMP9, MT1-MMP, TIMP1, and TIMP2 mRNA in valvular lesions of the heart. J Pathol 2001; 194: 225-31.
10. Cole WG, Chan D, Hickey AJ, Wilcken DE. Collagen composition of normal and myxomatous human mitral heart valves. Biochem J 1984; 219: 451-60.
11. Surazynski A, Miltyk W, Palka J, Phang JM. Prolidasedependent regulation of collagen biosynthesis. Amino Acids. 2008 ; 35: 731-8.
12. Palka JA, Phang JM. Prolidase activity in fibroblasts is regulated by interaction of extracellular matrix with cell surface integrin receptors. J Cell Biochem 1997; 67: 166-75.
13. Zanaboni G, Dyne KM, Rossi A, Monafo V, Cetta G. Prolidase deficiency: biochemical study of erythrocyte and skin fibroblast prolidase activity in Italian patients. Haematologica 1994; 79: 13-8.
14. Myara I, Myara A, Mangeot M, Fabre M, Charpentier C, Lemonnier A. Plasma prolidase activity: a possible index of collagen catabolism in chronic liver disease. Clin Chem 1984; 30: 211-5.
15. Erbagci AB, Araz M, Erbagci A, Tarakcioglu M, Namiduru ES. Serum prolidase activity as a marker of osteoporosis in type 2 diabetes mellitus. Clin Biochem 2002; 35: 263-8.
16. Altindag O, Erel O, Aksoy N, Selek S, Celik H, Karaoglanoglu M. Increased oxidative stress and its relation with collagen metabolism in knee osteoarthritis. Rheumatol Int 2007; 27: 339- 44.
17. Demirbag R, Yildiz A, Gur M, Yilmaz R, Elci K, Aksoy N. Serum prolidase activity in patients with hypertension and its relation with left ventricular hypertrophy. Clin Biochem. 2007; 40: 1020-5.
18. Ma LC, Chen MC, Chang HW. Plasma endothelin-1 levels in patients with rheumatic mitral stenosis and a history of cerebral thromboembolism. Chang Gung Med J 2004; 27: 794-800.
19. Atalar E, Ozturk E, Ozer N, Haznedaroglu IC, Kepez A, Coskun S et al. Plasma soluble osteopontin concentrations are increased in patients with rheumatic mitral stenosis and associated with the severity of mitral valve calcium. Am J Cardiol. 2006; 98: 817- 20.
20. Selcuk MT, Selcuk H, Maden O, Temizhan A, Aksu T, Dogan M et al. Relationship between inflammation and atrial fibrillation in patients with isolated rheumatic mitral stenosis. J Heart Valve Dis 2007; 16: 468-74.
21. Boldt A, Wetzel U, Lauschke J, Weigl J, Gummert J, Hindricks G et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 2004; 90: 400-5.
22. Myara I, Charpentier C, Lemonnier A. Optimal conditions for prolidase assay by proline colorimetric determination: application to imminodipeptiduria. Clin Chim Acta 1982; 125: 193-205.
23. Chinard FP. Photometric estimation of proline and ornithine. J Biol Chem 1952; 199: 91-5.
24. Surazynski A, Sienkiewicz P, Wolczynski S, Palka J. Differential effects of echistatin and thrombin on collagen production and prolidase activity in human dermal fibroblasts and their possible implication in beta1-integrin-mediated signaling. Pharmacol Res 2005; 51: 217-21.
25. Fan H, Liu W, Yan P. Pathological observation and immunohistochemistry study of Type I, III, IV collagen in mitral valve and cardiac interstitium of rheumatic disease. Zhonghua Yi Xue Za Zhi 1996; 76: 183-6.
26. Fenoglio JJ Jr, Wagner BM. Studies in rheumatic fever. VI. Ultrastructure of chronic rheumatic heart disease. Am J Pathol 1973; 73: 623-40.
27. Petelenz T, Drózdz M, Słomińska-Petelenz T, Jendryczko A, Kucharz E, Drazkiewicz U et al. Investigations upon collagen metabolites in blood serum and urine of patients with acquired valvular heart disease. Mater Med Pol 1989; 21: 199-205.
28. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O’Brien KD. Characterization of the early lesion of ‘degenerative’ valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994; 90: 844-53.
29. Rajamannan NM, Subramaniam M, Rickard D, Stock SR, Donovan J, Springett M et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 2003; 107: 2181-4.
30. Helske S, Lindstedt KA, Laine M, Mäyränpää M, Werkkala K, Lommi J et al. Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol 2004; 44: 1859-66.
31. Senboshi Y, Oono T, Arata J. Localization of prolidase gene expression in scar tissue using in situ hybridization. J Dermatol Sci 1996; 12: 163-71.